APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Sallman, MD, PhD
Moffitt Cancer Center, Tampa, US
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chu Nantes
Nantes, France
- Chu Nice
Nice, France
- Hôpital Saint-Louis
Paris, France
- Iuct Oncopole
Toulouse, France
- City of Hope
Duarte, California, United States
- Stanford University Cancer Research Center
Palo Alto, California, United States
- Yale Cancer Center
New Haven, Connecticut, United States
- Memorial Health Care System South Florida
Hollywood, Florida, United States
- Mayo Clinic Jacksonville
Jacksonville, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Robert H Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
- University of Chicago Medicine
Chicago, Illinois, United States
- University of Iowa Hospitals and Clinics, Holden Cancer Center
Iowa City, Iowa, United States
- Ochsner Cancer Institute
New Orleans, Louisiana, United States
- Johns Hopkins Medical Center
Baltimore, Maryland, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Mayo Clinic Rochester
Rochester, Minnesota, United States
- Washington University St. Louis
St Louis, Missouri, United States
- Cornell Medical Center
New York, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center, Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Jan 2019
- Primary completion
- 27 Nov 2020
- Completion
- 14 Jan 2022
- Last update posted
- 18 Mar 2025
- Registered enrollment
- 154
- Registry id
- NCT03745716
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.